Meeting NewsVideo

VIDEO: Aerie official shares phase 4 trial data on Rhopressa use

KOLOA, Hawaii — At Hawaiian Eye 2020, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses recent data, including results from the MOST phase 4 trial focusing on the use of Rhopressa (netarsudil ophthalmic solution 0.02%) in real-world experiences.

KOLOA, Hawaii — At Hawaiian Eye 2020, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses recent data, including results from the MOST phase 4 trial focusing on the use of Rhopressa (netarsudil ophthalmic solution 0.02%) in real-world experiences.

    See more from Hawaiian Eye/Retina Meeting